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Innate immunityISG20 is an interferon-inducible 3′–5′ exonuclease that inhibits replication of several human and animal RNA
viruses. However, the speciﬁcities of ISG20's antiviral action remain poorly deﬁned. Here we determine the
impact of ectopic expression of ISG20 on replication of several positive-strand RNA viruses from distinct viral
families. ISG20 inhibited infections by cell culture-derived hepatitis C virus (HCV) and a pestivirus, bovine
viral diarrhea virus and a picornavirus, hepatitis A virus. Moreover, ISG20 demonstrated cell-type speciﬁc
antiviral activity against yellow fever virus, a classical ﬂavivirus. Overexpression of ISG20, however, did not
inhibit propagation of severe acute respiratory syndrome coronavirus, a highly-pathogenic human
coronavirus in Huh7.5 cells. The antiviral effects of ISG20 were all dependent on its exonuclease activity.
The closely related cellular exonucleases, ISG20L1 and ISG20L2, did not inhibit HCV replication. Together,
these data may help better understand the antiviral speciﬁcity and action of ISG20.ilding, University of Tennessee
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Eukaryotes have evolved numerous intrinsic mechanisms to
combat microbial infections. The interferon (IFN) system is a major
innate antiviral pathway that is present in vertebrate cells. It is rapidly
activated in a tightly regulated fashion in response to viral infections.
Viral nucleic acids in viral genomes or generated during viralreplication present major pathogen associated molecular patterns
(PAMPs) to various cellular PAMP receptors, including the membrane
bound toll-like receptors (TLRs) or the cytoplasmic RIG-like receptors
(RLRs). Upon engagement with their cognate ligands, the TLRs and
RLRs recruit distinct adaptor proteins and transmit signals to
downstream kinases, culminating in the activation of the latent
transcription factors, IRF3 and NF-kB, which coordinately regulate
synthesis of type I IFNs (IFN-β and -α) (Yoneyama and Fujita, 2010).
Once secreted, IFNs act in a paracine/autocrine fashion through cell
surface IFN receptors, leading to the induction of hundreds of IFN
stimulated genes (ISGs) via the Jak-STAT pathway (Sen, 2001; Stark
et al., 1998). Although considerable progress has been made in
understanding the biological functions of a number of ISGs, much
remains to be learned about the role of the majority of ISGs in innate
antiviral defense. Apart from inducing cellular genes with direct
antiviral effects, IFNs also regulate activation of professional immune
cells, shaping subsequent adaptive immunity to virus infections
(Sen, 2001; Stark et al., 1998; Yoneyama and Fujita, 2010).
176 Z. Zhou et al. / Virology 409 (2011) 175–188In addition to serving as PAMPs for activation of the IFN system, viral
nucleic acids represent excellent targets which are subject to the direct
action of cellular antiviral proteins. Among the latter the RNase L
pathway represents a principal component of IFN's antiviral effector
mechanisms. A latent, ubiquitous endonuclease, RNase L is activated by
short oligoadenylates produced by the IFN-inducible, 2′5′-oligoadeny-
late synthetases followingviral infection. ActivatedRNase L exerts direct
antiviral effect by cleaving and degrading viral RNAs. It also cleaves
cellular 18S and 28S rRNAs, resulting in inhibition of protein synthesis
and cellular apoptosis, therebypreventingviral propagation (Silverman,
2007).RNase L-deﬁcientmicehave enhanced susceptibility to infections
by encephalomyocarditis virus (EMCV), Coxsackievirus, herpes simplex
virus 1 and West Nile virus (Flodstrom-Tullberg et al., 2005; Samuel et
al., 2006; Zheng et al., 2001; Zhou et al., 1997). Nevertheless, analyses of
mice triply deﬁcient for the threewell-characterized antiviral pathways,
PKR, RNase L, andMx demonstrated the presence of alternative effector
mechanisms which mediate IFN's antiviral actions (Zhou et al., 1999).
The IFN-stimulated gene 20 kDa protein (ISG20) has recently
emerged as a second IFN-regulated RNase that inhibits RNA virus
replication (Degols et al., 2007). ISG20, along with the closely related
ISG20L1 (a.k.a., apoptosis-enhancing nuclease, AEN) and ISG20L2,
belongs to the yeast RNA exonuclease 4 homolog (REX4) subfamily
within the DEDDh exonuclease family (Coute et al., 2008). Proteins of
this family can have both RNase and DNase activities; all have a large
structurally related, 150-aa long exonuclease domain (ExoIII) that
contains three distinct exonuclease motifs termed Exo I, Exo II and
Exo III deﬁned by four conserved acidic amino acids, DEDD and a
conserved histidine residue (Degols et al., 2007). Biochemical
analyses demonstrated that ISG20 is a 3′–5′ exonuclease that has a
preference for single-stranded (ss) RNA over ssDNA (Nguyen et al.,
2001). When overexpressed in vitro, ISG20 restricted infections by
EMCV, vesicular stomatitis virus, inﬂuenza virus, HIV and Sindbis
virus, although the antiviral efﬁciencies varied (Espert et al., 2003,
2005; Zhang et al., 2007). ISG20 also inhibited the replication of
subgenomic, genotype 1b hepatitis C virus (HCV) RNA replicons in
HEK293 cells (Jiang et al., 2008).
The mechanism underlying the antiviral action of ISG20 remains
poorly understood, as does its viral speciﬁcity (Degols et al., 2007).
The former is believed to involve degradation of viral RNAs by means
of the 3′–5′ exonuclease activity of ISG20, although possible actions
on cellular factors cannot be excluded (Degols et al., 2007). The
antiviral action of ISG20 is thought to operate poorly on double
stranded regions, as the RNase activity of ISG20 is negatively
regulated by the presence of a stem-loop structure at the 3′end of
the RNA substrate (Nguyen et al., 2001). However, only a small
number of RNA viruses have been tested thus far, precluding a better
understanding of the speciﬁcity and mechanism of action of ISG20.
Furthermore, it is not known whether the antiviral effect is shared by
other exonucleases that are closely related to ISG20. In this study, we
have compared in cell culture the effects of ISG20 on replication of
several positive-strand RNA viruses from distinct viral families,
including Flaviviridae [HCV, bovine viral diarrhea virus (BVDV)
and yellow fever virus (YFV)], Piconaviridae [hepatitis A virus
(HAV)] and Coronaviridae [severe acute respiratory syndrome
coronavirus (SARS-CoV)]. We show that (1) ISG20 inhibits replica-
tion of genotype 2a subgenomic HCV RNAs and cell culture derived
HCV, and that of HAV in cultured hepatoma cells; (2) ISG20 restricts
BVDV propagation in bovine kidney cells; (3) ISG20 demonstrates
cell-type speciﬁc antiviral effect against YFV, a classical ﬂavivirus;
(4) ISG20 does not inhibit SARS-CoV, a highly pathogenic novel
human coronavirus in Huh7.5 cells; 5) the antiviral effect against
HCV by ISG20 is not shared with ISG20L1 and ISG20L2. Our data
characterize the antiviral activities of ISG20 against distinct positive
strand RNA viruses and may help to better understand the
speciﬁcity and action of ISG20 in IFN-mediated antiviral innate
immunity.Results
Characterization of Huh7.5 cells stably expressing human ISG20 and a
related, catalytically inactive mutant ISG20
To determine how ISG20 affects HCV replication in hepatocytes,
we developed Huh7.5 cells that stably express human ISG20
(designated as 7.5-ISG20) and as controls, cells expressing the
catalytically inactive, D94G mutant ISG20 that is deﬁcient in
exonucleasae activity (Nguyen et al., 2001) (designated as 7.5-
ISG20m) and those expressing the empty vector (designated as 7.5-
Bsr), respectively, using retroviral-mediated gene transfer. Huh7.5
cells represent an Huh7 subline that is highly permissive for HCV
replication (Blight et al., 2002). In addition, Huh7 derived cells are
susceptible to many RNA viruses of distinct viral families (Devaraj
et al., 2007; Guix et al., 2007; Hattermann et al., 2005; Keskinen et al.,
1999; Lohmann et al., 1999; Muller et al., 2007; Tang et al., 2005; Yi
and Lemon, 2002). By establishing Huh7.5 cells stably expressing
ISG20/ISG20m, we were able to evaluate the effect of this ISG on
replication of many different viruses. To eliminate phenotypic
differences derived from variations among individual cell clones, we
utilized stable cell pools instead of clonal cell lines. The ectopically
expressed ISG20 (Fig. 1A) and ISG20m (data not shown) were
distributed in both nucleus and cytoplasm, and could be readily
detected in 7.5-ISG20 and 7.5-ISG20m cells by immunoblot analysis
using antibodies directed either against the myc epi-tag that was
introduced at the C-terminus of ISG20 (Fig. 1B, upper panel) or against
the ISG20 protein itself (lower panel), but not in the control vector
expressing 7.5-Bsr cells. Although they were stably expressed at high
levels (Fig. 1C), ISG20 and ISG20m did not alter growth characteristics
of Huh7.5 cells (Fig. 1D, compare 7.5-ISG20 and 7.5-ISG20m vs 7.5-Bsr
cells), nor did they affect the RIG-I signaling defect in Huh7.5 cells
(Sumpter et al., 2005) as determined by the absence of ISG56
induction following Sendai virus infection, irrespective of ISG20/
ISG20m expression status (Fig. 1E, compare lanes 3, 5, and 7 vs 9).
ISG20 inhibits replication of genotype 2a subgenomic HCV RNA replicons
and JFH1 virus infection by means of its catalytic activity in hepatoma
cells
Ectopic expression of ISG20 in HEK293 cells inhibits the replication
of a bicistronic, selectable subgenomic HCV-N (genotype 1b) RNA
replicon (Jiang et al., 2008). To determine how ISG20 affects HCV
replication in hepatocytes, we ﬁrst compared 7.5-ISG20, 7.5-ISG20m
and 7.5-Bsr cells for supporting the replication of genotype 2a JFH1
RNAs. We constructed a monocistronic subgenomic JFH1 RNA
replicon, SGRm-JFH1BlaRL, in which the coding sequences for most
of the HCV structural proteins (core-E1-E2-p7) and NS2 were
replaced by cDNA sequences encoding the blasticidin resistance
gene product directly fused to the N-terminus of Renilla luciferase,
FMDV autoprotease and ubiquitin, with the latter two directing
processing at the N-terminus of NS3 (Fig. 2A). SGRm-JFH1BlaRL RNA,
but not the RNA-dependent RNA polymerase defective GND mutant,
replicated continuously and robustly in transfected Huh7.5 cells,
expressing renilla luciferase as a measure of viral RNA ampliﬁcation
(Data not shown). SGRm-JFH1BlaRL replicated efﬁciently with similar
kinetics in 7.5-Bsr and 7.5-ISG20m cells, reaching a plateau at 48 to
96 h posttransfection (Fig. 2A). In contrast, its replicationwas severely
impaired in 7.5-ISG20 cells. At all time points examined, the
replication levels of SGRm-JFH1BlaRL RNA were always 5- to 10-fold
lower than those in 7.5-Bsr and 7.5-ISG20m cells (Fig. 2A). As controls,
the GND mutant replicon failed to replicate in any of these three
Huh7.5-derived cells (Fig. 3B).
We next determined how expression of ISG20 and ISG20m affects
propagation of JFH1 virus. In agreement with data from the replicon
experiments, we found that infectious progeny JFH1 virus release in
Fig. 1. Characterization of Huh7.5 cells stably expressing human ISG20 or its catalytically inactive mutant (ISG20m). (A) Immunoﬂuorescence staining of ISG20 expression (using
anti-myc mAb) in Huh7.5 cells mock-transfected (upper panels) or transiently transfected with a vector encoding myc-tagged ISG20 (lower panels). DAPI staining of nuclei was
shown in the right panels. Similar subcellular localization of ISG20 was observed in Huh7.5 cells stably transduced with human ISG20 (7.5-ISG20) or the D94G mutant ISG20 (7.5-
ISG20m) (data not shown). (B) Immunoblot analysis of ISG20 expression in 7.5-ISG20, 7.5-ISG20m and cells stably expressing the empty vector (Bsr). ISG20/ISG20m was probed
with anti-myc mAb (upper panel) and ISG20 (lower panel), respectively. Actin was detected with mAb anti-actin (upper panel), to demonstrate equal sample loading. Note that
ISG20m expressed to a slightly higher level than ISG20. It is unknown whether this reﬂects an auto-regulation of its own expression by ISG20. (C) Realtime PCR analysis of ISG20
mRNA levels in Huh7 and 7.5-ISG20 cells mock-treated or stimulated with IFN-α (500 U/ml) or infected with SeV (100 HAU/ml) for 16 h. mRNA abundances were normalized to
cellular 28S rRNA. Fold differences were calculated by dividing normalized mRNA abundance following various treatments by that of the mock-treated Huh7 cells. IFN-α induced
endogenous ISG20 expression by 7- to 15-fold in Huh7 and 7.5-ISG20 cells, while SeV upregulated ISG20 mRNA by 3-fold in Huh7 cells. (D) Triplicate wells of cells in 24-well plates
were cultured for the indicated time periods and cell proliferation assessed by MTT assay. (E) ISG20 or ISG20m expression does not reconstitute the RIG-I signaling defect in Huh7.5
cells. 7.5-Bsr, 7.5-ISG20, 7.5-ISG20m, and normal Huh7 cells weremock infected or infectedwith 100 HAU/mL of SeV for 16 h prior to cell lysis and immunoblot analysis of ISG56, SeV
and ISG20 (using anti-myc tag mAb). Asterisks in ISG56 panel denote nonspeciﬁc bands. Huh7.5 cells treated with recombinant human IFN-α for 16 h (lane 1) was included as a
positive control for ISG56 expression.
177Z. Zhou et al. / Virology 409 (2011) 175–188culture supernatants was reproducibly 7- to 10-fold lower in 7.5-
ISG20 cells than that in 7.5-Bsr and 7.5-ISG20m cells at 48–72 h
postinfection (MOI=0.05), while JFH1 virus yields were similar
between the latter two cultures (Fig. 2B). In aggregate, ISG20 not only
inhibits replication of genotype 1b HCV RNA replicons in HEK293 cells
(Jiang et al., 2008), but also acts to restrict genotype 2a HCV RNA
replication and JFH1 virus propagation in cultured hepatocytes. The
exonuclease activity is required for the antiviral activity of ISG20
against HCV.
ISG20 does not accelerate the degradation of HCV RNAs, nor does it
inhibit HCV IRES-dependent translation
The antiviral action of ISG20 is thought to involve the degradation
of viral RNAs by the 3′–5′ exonuclease activity of ISG20 (Degols et al.,
2007). To determine whether ISG20 promotes HCV RNA degradation,
we determined the stability of modiﬁed subgenomic HCV RNAs
encoding a luciferase reporter gene and also containing a lethal
mutation in the NS5B RNA-dependent RNA polymerase (Fig. 3A).Upon introduction into cells, these HCV RNAs express Renilla (SGRm-
JFH1BlaRL/GND) or ﬁreﬂy (NmLuc/ΔGDD) luciferases directed by HCV
IRES (SGRm-JFH1BlaRL/GND) or EMCV IRES (NmLuc/ΔGDD), respec-
tively. The luciferase activity serves as a read-out for HCV RNA
abundance. Due to the inability of these HCV RNAs to replicate, the
decay rate in luciferase activity represents the rate of HCV RNA
degradation. After electroporation into cells, the non-replicating JFH1
strain (genotype 2a) SGRm-JFH1BlaRL/GND RNA was degraded
rapidly in the ﬁrst 12 h, followed by a further slow decay in the
next 9 h, when the luciferase activity dropped to background level.
There was no appreciable difference among 7.5-Bsr, 7.5-ISG20 and
7.5-ISG20m cells (Fig. 3B). Similar results were obtained when the
replication-incompetent NmLuc/ΔGDD RNA (HCV-N strain, genotype
1b) was used in lieu of SGRm-JFH1BlaRL/GND RNA (Fig. 3C). These
data indicate that ISG20 does not seem to accelerate the degradation
of transfected HCV RNAs.
Translation of the positive-sense HCV RNA is directed by an IRES
within HCV 5′NTR, and leads to synthesis of viral proteins required for
HCV replication. We considered the possibility that ISG20 may exert
Fig. 2. ISG20 inhibits the replication of subgenomic JFH1 replicon and propagation of
cell culture derived JFH1 virus. (A) Upper panel, schematic representation of the
monocistronic, renilla luciferase (RLuc) encoding subgenomic replicon, SGRm-
JFH1BlaRL. The structural genes of JFH1, core-E1-E2-p7-NS2, were removed and
substituted with blasticidin S deaminase (Bla)−RLuc fusion gene, followed by foot and
mouse disease virus 2A autoprotease peptide and ubiquitin, which direct the processing
of the N-terminus of NS3. Lower panel, 7.5-Bsr, 7.5-ISG20, and 7.5-ISG20m cells were
transfected with SGRm-JFH1RL replicon RNA and harvested at indicated time points for
RLuc assay. The data shown represent the fold-increase in RLuc activity over that
present at 6 h in each cell type, and are representative of at least 3 independently
conducted experiments. (B) 7.5-Bsr, 7.5-ISG20, and 7.5-ISG20m cells were infected
with JFH1 virus at an MOI=0.05. At indicated time points, cell-free culture
supernatants were harvested and subject to infectious virus titer determination by
ﬂuorescent focus forming assay in naïve Huh7.5 cells. Data shown are representative of
at least two independently conducted experiments.
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we transfected 7.5-Bsr, 7.5-ISG20 and 7.5-ISG20m cells with pRL-HL
(Lerat et al., 2000), a dicistronic reporter vector expressing renilla
luciferase by cap-dependent translation, and a downstream ﬁreﬂy
luciferase coding sequence under cap-independent control of the HCVIRES (Fig. 3D). As shown in Fig. 3E, both cap-dependent and HCV IRES-
dependent translation efﬁciencies were comparable among the three
different cell populations, indicating that the antiviral action of ISG20
against HCV replication does not result from any effect on HCV IRES
activity.
ISG20m exerts dominant negative (DN) effect on the antiviral action of
IFN against intracellular HCV RNA replication
ISG20m exhibited a DN effect on the activity of endogenous ISG20
against VSV infection in HeLa cells (Espert et al., 2003). In contrast, we
did not observe increased permissiveness for JFH1 virus RNA
replication (Fig. 2A) or JFH1 infection (Fig. 2B) when comparing 7.5-
ISG20m and 7.5-Bsr cells. This lack of DN effect of ISG20m was most
likely due to the absence of detectable basal ISG20 protein expression
in Huh7.5 derived cells (Fig. 1B, lower panel). To determine whether
ISG20m inhibits the anti-HCV activity of IFN (which induces ISG20
expression), we pretreated 7.5-Bsr and 7.5-ISG20m cells with a high
concentration of human IFN-α (1000 U/ml) to induce a cellular
antiviral state. IFN was then removed and cells were transfected with
SGRm-JFH1BlaRL replicon RNA to determine the kinetics of intracel-
lular HCV RNA replication (Fig. 4A). In the absence of IFN
pretreatment, both 7.5-Bsr and 7.5-ISG20m cells supported robust
HCV RNA replication, which reached plateau at 48–72 h posttransfec-
tion. There was no appreciable difference between the two cell
populations. IFN pretreatment strongly suppressed SGRm-JFH1BlaRL
RNA replication in both 7.5-Bsr and 7.5-ISG20m cells, but was
substantially less effective in 7.5-ISG20m cells than in 7.5-Bsr cells.
At 48 and 72 h posttransfection, HCV RNA replication was reduced by
IFN pretreatment by 427-fold and 68-fold, respectively, in 7.5-Bsr
cells, but was only decreased by 91-fold and 16-fold, respectively in
7.5-ISG20m cells (Fig. 4A). This difference could not be attributed to
an impaired response through Jak-STAT signaling to IFN in 7.5-
ISG20m cells, as IFN induction of two well-characterized ISGs, ISG56
and MxA, was of similar efﬁciency in 7.5-ISG20m cells compared with
7.5-Bsr cells (Fig. 4C). In aggregate, these data suggest that ISG20 is a
signiﬁcant contributor to the IFN antiviral action against intracellular
HCV RNA replication, and that this is inhibited by ISG20m.
Next, we determined how ISG20m affects IFN's anti-HCV action in
the context of JFH1 virus infection. Towards this end, we pretreated 7.5-
Bsr and 7.5-ISG20m cells with a range of IFN-α concentrations (0, 5, 10,
25 and 100 U/ml) to induce a cellular antiviral state. IFN was then
removed and cells were infected with JFH1 virus at an MOI of 0.05. At
48 h postinfection, culture supernatants were examined for infectious
progeny virus yields by FFU assay (Fig. 4B).We found that pretreatment
of cellswith as low as 5 U/ml of IFN-αwas able to reduce infectious JFH1
virusproductionby40%,with noobvious further reduction at higher IFN
concentrations. Of note, the reduction of progeny virus yields by IFN
pretreatment did not differ between 7.5-Bsr and 7.5-ISG20m cells,
regardless of the IFN concentrations used. This suggests that ISG20
mediated inhibition of intracellular HCV RNA replication represents
only a fraction of IFN's effects against HCV infection. Conceivably, IFN
may also target various steps in HCV life cycle other than intracellular
HCV RNA replication, such as viral entry, uncoating, packaging and
release, etc (Stark et al., 1998), which may not be targeted by ISG20's
exonuclease activity. Such antiviral mechanisms may not be competed
by the ectopically expressed ISG20m.
ISG20L1 and ISG20L2 do not inhibit HCV replication
ISG20L1 and ISG20L2 are the two most closely related members to
ISG20 in the REX4 gene subfamily within the DEDDh exonuclease
family (Coute et al., 2008; Lee et al., 2005). Both proteins have an
ExoIII exonuclease domain highly similar to that of ISG20 within their
C-terminal portions (Fig. 5A). However, unlike ISG20 which is only
composed of an ExoIII domain, ISG20L1 and ISG20L2 have additional
Fig. 3. ISG20 does not accelerate the degradation of transfected HCV RNAs, nor does it inhibit HCV IRES-directed translation. (A) Schematic representation of the replication-
incompetent, luciferase-encoding, subgenomic HCV RNAs derived from JFH1 (SGRm-JFH1BlaRL/GND) and HCV-N (NmLuc/ΔGDD) sequences. SGRm-JFH1BlaRL/GND is identical to
SGRm-JFH1BlaRL (Fig. 2A) except for the aa mutation in the GDD motif (to GND) in NS5B (indicated by “*”). In NmLuc/ΔGDD, the GDD motif in NS5B is deleted (indicated by “Δ”).
Translation of Fireﬂy luciferase (FFLuc), FMDA 2A autoprotease and the downstream NS3 to NS5B polyprotein is directed by EMCV IRES. (B) and (C) 7.5-Bsr, 7.5-ISG20 and 7.5-
ISG20m cells were transfected with in vitro transcribed SGRm-JFH1BlaRL/GND (B) or NmLuc/ΔGDD (C) RNAs. At indicated time points post transfection, cells were lysed and
subjected to Renilla (B) or Fireﬂy (C) luciferase activity assays. HCV RNA degradation is reﬂected in the percent decrease in luciferase activity (normalized to that at 3 h post-
transfection, when luciferase activity results from translation of initial input HCV RNA). (D) Schematic showing the organization of the bicistronic reporter construct, pRL-HL. CMV-
IE: CMV immediate early promoter; BGHpA: bovine growth hormone polyadenylation signal. (E) 7.5-Bsr, 7.5-ISG20, and 7.5-ISG20m cells in triplicate wells were transfected with
pRL-HL for 24 h and then lysed for dual luciferase assay determining the translation efﬁciencies directed by 5′cap (RLuc) and HCV IRES (FFLuc), respectively. Results are normalized
to the luciferase activity from transfected Bsr cells (100%).
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the N-terminal part of ISG20L1 and ISG20L2 is poorly understood, but
could determine the predominant nuclear localization of these two
proteins (Coute et al., 2008; Lee et al., 2005). In agreement with these
previous studies, we found that both ISG20L1 and ISG20L2 were
expressed exclusively within the nucleus of transfected Huh7.5 cells,
resembling a nuclear body localization pattern (Fig. 5B). To determine
whether these two ISG20-like proteins have antiviral activity againstHCV, we attempted to establish Huh7.5 cells stably expressing
ISG20L1 and ISG20L2, respectively, using retroviral mediated gene
transfer. We were able to generate stable Huh7.5 pools expressing
ISG20L1 (Fig. 5C). However, efforts to obtain ISG20L2 expressing cells
have been unsuccessful thus far—virtually no cells survived the
selection process after infection of ISG20L2-encoding retroviruses.
The reason for this failure remains unclear, but could reﬂect cellular
toxicity associated with long-term ectopic expression of ISG20L2.
Fig. 4. The exonuclease-deﬁcient ISG20 mutant inhibits the antiviral action of IFN against intracellular HCV RNA replication. (A) 7.5-Bsr and 7.5-ISG20m cells were mock-treated or
pretreated with 1000 U/mL of recombinant human IFN-α for 18 h. IFN was then removed and cells transfected with SGRm-JFH1RL replicon RNA. Replication kinetics was analyzed
the same way as in Fig. 2A. Data shown were representative of three independent experiments. (B) Triplicate wells of 7.5-Bsr and 7.5-ISG20m cells were pretreated with 0, 5, 10, 25
and 100 U/mL of IFN-α for 24 h. After removal of IFN, cells were infected with JFH1 virus at an MOI=0.05. Cell free culture supernatants were harvested at 48 h postinfection and
infectious virus titer determined by ﬂuorescent focus forming assay. Data are presented as percentage of virus titer relative to cells treatedwith 0 U/mL IFN. Data are representative of
2 independently conducted experiments. (C) 7.5-Bsr and 7.5-ISG20m cells respond similarly to IFN. Cells were treated with 0, 10, 50, 100, and 1000 U/mL of IFN-α for 7 h prior to
total RNA extraction and realtime PCR analysis of ISG56 and MxA mRNA expression. Fold change of each gene was calculated by normalizing the data to 7.5-Bsr mock treated cells
(there was no difference in the baselines of ISG56 and MxA mRNAs between mock-treated 7.5-bsr and 7.5-ISG20m cells).
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SGRm-JFH1BlaRL replicon replicated efﬁciently in 7.5-ISG20L1 cells as it
did in 7.5-Bsr cells (Fig. 5D). In agreement with this, intracellular core
proteinaccumulationafter JFH1virus infectionwasgreatly reduced in7.5-
ISG20 cells compared with that in 7.5-Bsr and 7.5-ISG20L1 cells, but was
comparable between the latter two (Fig. 5E). Thus, unlike ISG20, ISG20L1
does not have antiviral activity against HCV in cultured hepatoma cells.
Because we were unable to generate stable cells expressing ISG20L2,
we adopted a transient co-transfection strategy in determining the effect
of ISG20L2onHCVRNAreplication.Weco-transfectedHuh7cellswith theFig. 5. ISG20L1 and ISG20L2 do not inhibit HCV replication. (A) Amino acid sequence alignme
of the sequences indicate amino acid positions. The three exonuclease motifs (I, II and III) a
heavy grey-shaded letters, while the semi-identical residues are in light grey-shaded letters
exonuclease superfamily are in black-shaded letters. The ExoIII domain amino acid ident
(B) Subcellular localizations of ISG20L1 and ISG20L2 in transiently transfected Huh7.5 cells. IS
counterstained blue by DAPI. ISG20L1 showed a similar localization pattern in 7.5-ISG20L1
actin expression in 7.5-bsr (lane 1) and 7.5-ISG20L1 (lane 2) cells. (D) Replication kinetics of
and analyzed similarly to Fig. 2A. Data shown are representative of two independently condu
virus at an MOI of 0.05. At indicated time points, cell lysates were subject to immunoblot an
conducted experiments. (F) Huh7 cells were transiently co-transfected with SGRm-JFH1Bla
respectively, at a ratio of 1:6 using lipofectamine 2000. Replication of SGRm-JFH1RL replicon
at 6 h posttransfection (upper panel). In lower panel, expression of ISG20, ISG20L1 and
immunoblotted to demonstrate equal sample loading.SGRm-JFH1BlaRL replicon RNA and the ISG20L2 encoding plasmid at a
ratio of 1:6 and monitored HCV RNA replication by determining the fold
increase in luciferase activity at 72 h over at 6 h post-transfection. As
controls, cells were co-transfected with the replicon RNA and ISG20-
encoding plasmid (as a positive control) or an empty vector, or the
ISG20L1 encoding vector (as negative controls). Although ISG20 strongly
inhibited SGRm-JFH1BlaRL replication compared with the empty vector,
ISG20L2 and ISG20L1 did not (Fig. 5F). Together, the antiviral activity of
ISG20 against HCV is not sharedwith the closely related proteins, ISG20L1
and ISG20L2.nt of the ExoIII domains of ISG20, ISG20L1 and ISG20L2. Numbers shown on the left side
re marked by top braces. The identical residues throughout the three sequences are in
. The ﬁve conserved amino acid residues (D, E, D, D and H) characteristic of the DEDDh
ities between ISG20 and ISG20L1, ISG20 and ISG20L2 are 57% and 51%, respectively.
G20L1 and ISG20L2 were immunostained green using anti-mycmAb, while nuclei were
cells (data not shown). (C) Immunoblot analysis of ISG20L1 (using anti-myc mAb) and
SGRm-JFH1RL replicon in 7.5-Bsr, 7.5-ISG20, and 7.5-ISG20L1 cell. Cells were transfected
cted experiments. (E) 7.5-Bsr, 7.5-ISG20, and 7.5-ISG20L1 cells were infected with JFH1
alysis of HCV core and actin expression. Results are representative of 2 independently
RL replicon RNA and an empty vector or plasmid encoding ISG20, ISG20L1, or ISG20L2,
was determined by calculating the fold increase of luciferase activities at 72 h over those
ISG20L2 proteins were analyzed by western blot using anti-myc mAb. Actin was
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Classiﬁed within the genus pestivirus in the family Flaviviridae,
BVDV shares similar genome structure and replication strategy with
HCV. It has been themost widely used in vitro surrogatemodel system
for the identiﬁcation and characterization of antiviral agents for use
against HCV (Buckwold et al., 2003) before the HCV cell culture
system became available. Since ISG20 suppresses HCV RNA replica-Fig. 6. ISG20 inhibits BVDV infection in MDBK cells. (A) Immunostaining of ISG20/ISG20m e
(right) cells. (B) Upper panel, immunoblot analysis of ISG20 and ISG20m expression (using
was blotted to show equal sample loading (C). Duplicate wells of BK-ISG20m (upper two ro
increasing MOIs (from right to left, 0.0003 through 0.3) of the cytopathic NADL strain of BVD
of two independently conducted experiments. (D) BK-bsr, BK-ISG20 and BK-ISG20m cells w
time points, cell-free culture supernatants were harvested and viral titers were determ
independently conducted experiments.tion, we asked the question whether replication of the closely related
BVDV is also subject to the inhibitory action of ISG20. Toward this end,
we established MBDK cell pools stably expressing ISG20 (designated
as BK-ISG20), ISG20m (designated as BK-ISG20m) and the control
vector (designated as BK-Bsr), respectively, by retroviral mediated
gene transfer. In contrast to the control BK-Bsr cells, BK-ISG20 and
BK-ISG20m cells expressed abundant myc-tagged ISG20 or ISG20m
protein (Figs. 6A and B), which demonstrated both cytoplasmic andxpression using anti-myc tag mAb in BK-Bsr (left), BK-ISG20 (middle) and BK-ISG20m
anti-myc tag mAb) in BK-Bsr, BK-ISG20 and BK-ISG20m cells. In lower panel, beta-actin
ws) and BK-ISG20 (lower two rows) cells grown in a 96-well plate were infected with
V for 66 h prior to cell ﬁxation and crystal violet staining. Image shown is representative
ere infected with BVDV NADL at an MOI of 0.01 (left) or 0.001 (right). At the indicated
ined by TCID50 assay on naïve MDBK cells. Data shown are representative of two
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ISG20 in human cells (Fig. 1A) (Espert et al., 2003, 2006). When
infected with the cytopathic BVDV NADL virus at a range of increasing
MOIs (0.0003 to 0.3), BK-ISG20 cells had substantially less CPE and
more cell survival than did BK-ISG20m cells (Fig. 6C). In agreement
with this, progeny BVDV yields from infected BK-ISG20 cells were
consistently about 1-log lower than those in BK-Bsr and BK-ISG20m
cells at 48 and 72 h postinfection, with the latter two being similar
(MOI=0.01 and 0.001, shown in Fig. 6D). We conclude from these
experiments that similar to HCV, BVDV is also sensitive to the antiviral
action of ISG20 in cell culture.
Cell-type speciﬁc antiviral effect of ISG20 against YFV infection
Next, we determined how ISG20 affects the replication of YFV, a
prototype member of the genus ﬂavivirus in the family Flaviviridae.Fig. 7. Cell-type speciﬁc antiviral effect of ISG20 against YFV infection. 7.5-Bsr, 7.5-ISG20 an
YFV 17D strain (MOI=0.1) (panel C). At indicated time points, cell-free culture supernatants
A and C). Data shownwere representative of two independently conducted experiments. (B)
in cell lysates under conditions in panel A. (D) HEK293-FLP-IN T-Rex cells that condition
tetracycline for 2 days, to induce or repress ISG20/ISG20m expression, respectively, and
supernatants were harvested and progeny viral titers were determined by ﬂuorescent focu
analysis of YFV NS3 (arrow head), actin (arrow) and ISG20/ISG20m (using anti-Flag antibod
experiments.When infected with the virulent Asibi strain of YFV (MOI=0.1), all
three Huh7.5 derived cells supported efﬁcient virus growth. There
were no appreciable differences in infectious progeny virus release
(Fig. 7A) and intracellular accumulation of YFV NS3 antigen (Fig. 7B)
in the 3- to 4-day observation period, regardless of ISG20/ISG0m
expression status. The results did not differ when the vaccine strain
(17D) of YFV was used in lieu of Asibi strain for the infection (Fig. 7C).
Thus, in contrast to its effect on HCV, ISG20 does not inhibit YFV
propagation in hepatoma Huh7.5 cells.
To determine whether the lack of antiviral activity against YFV by
ISG20 in huh7.5 cells was a cell-type speciﬁc phenomenon, we took
advantage of HEK293 FLP-IN T-Rex cells with tet-regulated condi-
tional expression of ISG20 or ISG20m (Jiang et al., 2008). Cells were
cultured to induce (+tet) or repress (−tet) ISG20 or ISG20m
expression, followed by infection with YFV-17D virus (MOI=0.1)
for 4 days. YFV-17D grew at amuch slower rate in HEK293 cells than itd 7.5-ISG20m cells were infected with YFV Asibi strain (MOI=0.1) (panels A and B) or
were harvested and viral titers determined by ﬂuorescent focus-forming assay (panels
Immunoblot analysis of YFV NS3, ISG20 (using anti-myc antibody), and actin expression
ally express ISG20 or ISG20m were cultured in the presence or absence of 1 μg/ml
subsequently infected with YFV 17D virus (MOI=0.1) for 4 days. Cell-free culture
s-forming assay (panel D). Cell lysates were harvested and subjected to immunoblot
y) proteins (panel E). Data shown are representative of two independently conducted
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ﬁrst detected at 48 h post-infection (Fig. 7D). We found that induction
of ISG20, but not ISG20m, reduced progeny YFV production by 2–3
logs at 48 to 96 h post-infection (Fig. 7D). Consistent with this,
accumulation of YFV NS3 antigen was diminished in HEK293 cells
expressing ISG20 (Fig. 7E, compare lanes 5 and 6 vs 2 and 3) but not in
cells induced for ISG20m expression (Fig. 7E, compare lanes 11 and 12
vs 8 and 9). Collectively, although ISG20 has no demonstrable
antiviral activity against YFV in Huh7.5-derived cells, it potently
inhibits YFV replication in HEK293 cells and such an effect depends on
its catalytic activity.
ISG20 inhibits HAV replication
HAV is a picornavirus that infects mainly hepatocytes, causing
acute hepatitis in vivo (Martin and Lemon, 2006). To determine
whether ISG20 inhibits HAV replication, we ﬁrst compared the
replication efﬁciency of a subgenomic HAV RNA replicon encoding
luciferse (HAV-Luc, Fig. 8A) among 7.5-Bsr, 7.5-ISG20, and 7.5–
ISG20m cells. HAV-Luc replicated efﬁciently in both 7.5-Bsr and 7.5-
ISG20m cells with similar kinetics, resulting in an increase in
luciferase activity over 72 h followed by a plateau later. In contrast,
replication of HAV-Luc was substantially compromised in 7.5-ISG20
cells, resulting 5- to 7-fold lower luciferase activity than that observed
with 7.5-Bsr and 7.5-ISG20m cells 72–96 h posttransfection (Fig. 8B).
These results suggest that ISG20 expression restricts HAV RNAFig. 8. ISG20 inhibits HAV replication. (A) Schematic representation of the HAV-Luc replicon
7.5-ISG20m cells. Data shown are representative of 3 independent experiments. (C and D) H
the presence or absence of 2 μg/ml tetracycline for 3 days, to induce or repress ISG20/ISG20m
for 5 days. Then cell lysates were harvested and immunoblotted for expression of ISG20/ISG2
determined by infrared ﬂuorescent immunofocus assay of 10-fold serially diluted samples o
was stained with secondary antibody conjugate only.replication in Huh7.5 cells. To determine whether ISG20 inhibits
HAV replication in the context of virus infection, HEK293 FLP-IN T-Rex
cells with tet-regulated expression of ISG20 or ISG20m were cultured
to induce (+tet) or repress (−tet) ISG20 or ISG20m expression
(Fig. 8C), followed by infection with HAV-18f virus for 5 days.
Induction of ISG20 was associated with a reproducible, 2-fold
reduction in progeny HAV yield, while no such effect was observed
upon ISG20m expression (Fig. 8D). Collectively, ISG20 inhibits HAV
replication in both hepatic and non-hepatic cells and the anti-HAV
effect is dependent on the exonuclease activity of ISG20.
ISG20 does not inhibit propagation of SARS-CoV in Huh7.5 cells
SARS-CoV is a highly pathogenic human coronavirus which was
just recognized in 2003. Unlike other known human coronaviruses
which are usually associated with mild upper respiratory tract
infection, infection with SARS-CoV causes severe lower respiratory
illness with a mortality rate of ~10% (Peiris et al., 2004, 2003).
Although there is no speciﬁc antiviral therapy available for treatment
of SARS, IFN is known to inhibit SARS-CoV replication in vitro and
protect against SARS-CoV infection in vivo (Cinatl et al., 2003;
Haagmans et al., 2004; Spiegel et al., 2004; Zheng et al., 2004). Since
ISG20 was highly upregulated in lungs of cynomolgus macaques
experimentally infected with SARS-CoV (de Lang et al., 2007), we set
out to determine whether ISG20 contributes to the antiviral action of
IFN against SARS-CoV, taking advantage of the fact that SARS-CoV(Yi et al., 2002). (B) Replication kinetics of HAV-luc replicon in 7.5-Bsr, 7.5-ISG20 and
EK293-FLP-IN T-Rex cells that conditionally express ISG20 or ISG20m were cultured in
expression, respectively, and subsequently infected with HM175/18f virus (MOI=1)
0m (using anti-Flag antibody) and GAPDH (panel C), and HAV infectious virus yield was
n FRhK-4 cells (panel D). In panel D, the control dish in ISG20m (+tet) at 106 dilution
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Tang et al., 2005). When infected at a low MOI (0.01), 7.5-Bsr, 7.5-
ISG20 and 7.5-ISG20m cells released similar amount of progeny
viruses in culture medium at all time points during the 3-day
observation period (Fig. 9A). Consistent with this, intracellular
accumulation of SARS-CoV nucleocapsid protein was comparable
among these cell populations, regardless of the ISG20/ISG20m
expression status (Fig. 9B). These data reveal that ISG20 does not
inhibit SARS-CoV replication in hepatoma Huh7.5 cells.
Discussion
In this study, we have characterized the antiviral spectrum of
ISG20 in vitro by determining the effects of ectopically expressed
ISG20 on replication of a number of distinct positive strand RNA
viruses. Previously, it has been shown that ISG20 exhibits antiviral
activity against vesicular stomatitis virus, EMCV, inﬂuenza virus, HIV,
and Sindbis virus (Espert et al., 2003, 2005; Zhang et al., 2007). It is
demonstrated in the current study that ISG20 also inhibits HAV, BVDV
and cell culture derived HCV (JFH1 virus). Furthermore, we report
that ISG20 exhibits cell-type speciﬁc antiviral activity against YFV
infection (Fig. 7)—while ISG20 had no demonstrable anti-YFV effect in
Huh7.5-derived cells, it potently inhibited YFV replication in HEK293
cells. The latter result is in line with a very recent report which
demonstrated that ISG20 inhibited infections by two closely related
ﬂaviviruses to YFV, West Nile virus and Dengue virus, when
ectopically expressed in HEK293 cells (Jiang et al., 2010). At present,Fig. 9. ISG20 does not inhibit SARS-CoV replication in Huh7.5 cells. (A) 7.5-Bsr, 7.5-
ISG20 and 7.5-ISG20m cells were infected with SARS-CoV, Urbani strain (MOI=0.01).
At indicated time points, cell-free culture supernatants were harvested and viral titers
determined by TCID50 assay on Vero E6 cells. Data shown were representative of two
independently conducted experiments. (B) Immunoblot analysis of SARS-CoV
nucleocapsid (N), ISG20/ISG20m (using anti-myc mAb), and actin expression in cell
lysates under conditions of panel A.we do not know what cellular factor(s) contributes to the disparate
anti-YFV activity of ISG20 between Huh7.5 and HEK293 cells.
Nonetheless, our data suggests the need for cautionwhen interpreting
results obtained from different cell types. Thus, although we did not
observe an antiviral effect of ISG20 on propagation of SARS-CoV in
Huh7.5 cells (Fig. 9), further studies are needed to determine whether
this holds true in other cell types that support efﬁcient SARS-CoV
replication.
Recently, ISG20 was reported to inhibit genotype 1b (HCV-N
strain) subgenomic HCV RNA replicons when stably expressed in
HEK293 cells (Jiang et al., 2008). The current study shows that ISG20
also acts to inhibit the replication of genotype 2a (JFH1) subgenomic
replicon as well as propagation of cell culture-derived HCV (JFH1
virus) in cultured hepatocytes. Furthermore, our results show that
ectopically expressed ISG20 inhibits HCV RNA replication and
progeny virus release in Huh7.5 cells that lack both RIG-I and TLR3
viral RNA sensing pathways which recognize HCV replication and
trigger IFN antiviral responses (Li et al., 2005a; Saito et al., 2008;
Sumpter et al., 2005;Wang et al., 2009). Therefore, the antiviral action
of ISG20 against HCV infection does not seem to depend on an IFN-
inducible factor. This is in contrast to what has been shown for the
zinc-ﬁnger antiviral protein, an ISG that requires an IFN-induced
factor to inhibit alphavirus virion production (MacDonald et al.,
2007). However, our results do not rule out the possibility that one or
more IFN-stimulated cellular factors may enhance the antiviral
activity of ISG20.
The demonstrated antiviral activities of ISG20 against HCV, HAV,
BVDVandYFV all require the exonuclease activity of ISG20, as theywere
consistently abrogated by the D94G mutation that speciﬁcally disrupts
the active site of ISG20 ExoIII domain (Figs. 2, 6–8)(Jiang et al., 2008;
Nguyen et al., 2001). The currently proposed effector mechanism of
ISG20 involves the degradation of viral RNAs by the 3′–5′ exonuclease
activity of ISG20 (Degols et al., 2007). However, precisely how ISG20
acts to inhibit HCV, HAV, YFV and BVDV infection is not known. Our
results show that ISG20doesnot enhance thedegradationof transfected
HCV RNA, regardless of the virus strains (JFH1, genotype 2a and HCV-N,
genotype 1b) tested (Fig. 3A–C). While this is a little surprising, it is
possible that ISG20 exerts its antiviral action by targeting a cellular
factor(s) required for virus replication (Degols et al., 2007). However, it
is also possible that ISG20 only recognizes HCV RNAs which are
associated with replication complex and/or reside in certain cellular
compartments. It should benoted that ourRNAstability data (Fig. 3A–C)
were from replication defective RNAs andhence gave no information on
whether ISG20 promotes the degradation of negative strand HCV RNA,
which could constitute an antiviral mechanism of ISG20. We show that
ISG20 does not affect HCV IRES-mediated translation (Fig. 3E), an
essential step before HCV proteins, including the nonstructural proteins
involved in viral RNA replication, are made. Furthermore, we demon-
strate that ectopically expressed, D94G mutant ISG20 suppresses IFN's
antiviral effect on replication of subgenomic HCV RNAs in hepatoma
cells (Fig. 4A), indicating that ISG20 is a critical component in executing
IFN's antiviral actions against HCV RNA replication in hepatocytes.
Conceivably, the catalytically-inactive ISG20 mutant may act as a DN
inhibitor that competes with ISG20 in recognizing/associating with the
viral/cellular substrate(s). When JFH1 virus was used in probing IFN's
antiviral action, the DN effect of the D94G mutant ISG20 was not as
evident (Fig. 4B). This is not surprising, as IFN likely targets multiple
stages of HCV life cycle which are not recapitulated in the HCV RNA
replicon system and are probably not subjected to ISG20's action, such
as viral attachment, entry, uncoating, packaging, and egress, etc.
ISG20L1 and ISG20L2 represent the two most closely related 3′ to
5′ exoribonucleases to ISG20 (Coute et al., 2008; Lee et al., 2005). Both
share a highly similar EXOIII domain with ISG20, with amino acid
identities of 57% (ISG20L1) and 51% (ISG20L2) compared with ISG20,
respectively. The biological functions of these two ISG20-like proteins
are not well understood. ISG20L1 (a.k.a., AEN) is induced by p53
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efﬁcient DNA fragmentation in p53-dependent apoptosis (Lee et al.,
2005). ISG20L2 is involved in ribosome biogenesis at the level of 5.8S
rRNA maturation, more speciﬁcally in the processing of the 12S
precursor rRNA (Coute et al., 2008). Our data analyzing HCV RNA
replication efﬁciencies in hepatoma cells ectopically expressing
ISG20L1 or ISG20L2 did not reveal an antiviral function of these two
ISG20-like proteins, at least against HCV (Fig. 5). While there may be
intrinsic differences in substrate preference of ISG20L1 and ISG20L2
from that of ISG20, it is of note that ISG20L1 and ISG20L2 localize
within nucleus (Fig. 5B) (Coute et al., 2008; Lee et al., 2005), whereas
ISG20 is distributed in both nucleus and cytoplasm (Figs. 1A and 6A)
(Espert et al., 2003, 2006). It is possible that ISG20L1 and ISG20L2 do
not have access to HCV RNA and/or cellular factors essential for HCV
replication, which are targeted by ISG20.
ISG20mRNA is highly upregulated in liver of chimpanzees infected
with HCV or following intravenous administration of IFN (Bigger et al.,
2001; Lanford et al., 2006). In the liver of chimpanzees acutely
infected with hepatitis B virus (HBV), ISG20 was induced during the
viral clearance stage (Wieland et al., 2004). Interestingly, ISG20, when
ectopically expressed in HepG2 cells, reduces the secretion of HBs and
HBe antigens in transfected HepG2 cells (Hao and Yang, 2008). The
broad antiviral activities of ISG20 against multiple, distinct hepatitis
viruses (HAV, HCV and HBV) indicate that ISG20 is an important
antiviral effector molecule downstream of IFN signaling in innate
defenses of the liver.
Materials and methods
Plasmids
Conventional PCR techniques were used to construct retroviral
expression vectors encoding human ISG20, ISG20L1 and ISG20L2,
respectively, in pCX4Bsr backbone (Akagi et al., 2003). pCX4Bsr-
ISG20-myc encodes C-terminal myc-6Xhis tagged human ISG20,
while pCX4Bsr-ISG20L1 and pCX4Bsr-ISG20L2 encode C-terminal
myc-tagged human ISG20L1 and ISG20L2, respectively. pCX4Bsr-
ISG20m-myc contains cDNA sequence encoding the catalytically
inactive mutant ISG20. It is different from pCX4Bsr-ISG20-myc in
that the codon Asp 94 (GAC) of human ISG20 was converted to Gly
(GGC). The bicistronic reporter plasmid pRL-HL and subgenomic
pHAV-Luc replicon construct have been described (Lerat et al., 2000;
Yi and Lemon, 2002).
The monocistronic pSGRmJFH1BlaRL replicon was constructed as
follows. pFL-J6/JFH-5′C19Rluc2AUbi (kindly provided by C. Rice)
(Tscherne et al., 2006) was ﬁrst modiﬁed to include blasticidin
resistance gene directly fused to the N-terminus of Renilla luciferase.
To achieve this, the EcoRI–MluI fragment containing the entire 5′NTR
and the ﬁrst 19 core-coding sequences in pFL-J6/JFH-5′C19Rluc2AUbi
was replaced with a similarly digested fragment ampliﬁed by PCR
from pSGR-JFH1-blast (kindly provided by G. Luo) (Chang et al., 2006)
using the primers, EcoRIT7+, cagtgaattctaatacgactcactatag, and
MluIBlanostop−, gtcatacgcgtGCCCTCCCACACATAAC. The resulting
plasmid was named as pJ6JFH1BlaRL. Subsequently, QuikChange
site-directed mutagenesis was conducted to remove the HCV
Core-E1-E2-p7-NS2 coding sequences downstream of the ubiquitin
sequence, leading to a direct fusion of N-terminus of NS3 to ubiquitin.
The resulting plasmid was digested with AgeI and AvrII to release the
cDNA fragment (hereafter referred as fragment L) containing partial
5′NTR, the ﬁrst 12 aa coding sequence of Core, the blasticidin
resistance gene, full Renilla luciferase coding sequence, FMDV 2a
autoprotease sequence, ubiquitin and partial NS3 coding sequence.
pSGR-JFH1 (Kato et al., 2003) (kindly provided by T. Wakita) was
digested with AgeI and AvrII to remove the partial 5′NTR, the ﬁrst 19
aa coding sequence of Core, the neomycin phosphotransferase II gene,
EMCV IRES and partial NS3 coding sequence, and used as a vector forligation with fragment L to generate the monocistronic replicon,
pSGRmJFH1BlaRL. A replication defective mutant replicon,
pSGRmJFH1BlaRL/GND, was constructed the same way except that
pSGR-JFH1/GND was used as the vector backbone for ligation with
fragment L. The fragment L in both constructs was fully sequenced to
conﬁrm its authenticity. A monocistronic, replication defective
mutant replicon of HCV-N strain, NmLuc/ΔGDD, was constructed by
replacing the cDNA fragment containing the neomycin phospho-
transferase II gene and EMCV IRES in NNeo/3-5B/ΔGDD (Ikeda et al.,
2002) with a cDNA cassette containing EMCV IRES, ﬁreﬂy luciferase
gene and FMDV 2a autoprotease, with the latter directly fused to the
N-terminus of NS3. In addition, the start codon of core was converted
to a termination codon (TAG).
Replicon RNAs were prepared from plasmid DNA templates
linearized with XbaI (pSGRmJFH1BlaRL, pSGRmJFH1BlaRL/GND and
NmLuc/ΔGDD) and XmaI (pHAV-Luc) using the T7 Megascript kit
(Ambion) and were puriﬁed by DNase I treatment and LiCl
precipitation. RNAs were quantiﬁed by optical density, and the
quality and concentration were conﬁrmed by agarose gel
electrophoresis.
Cells and transfections
Human hepatoma cells Huh7.5 and Huh7, African green monkey
kidney cells FRhK4 and Vero-E6 were maintained by conventional
techniques. MDBK cells were cultured in Dulbecco's modiﬁed Eagle's
medium supplemented with 10% horse serum, penicillin and
streptomycin. HEK293 FLP-IN T-Rex cells expressing ISG20 and
mutant ISG20 were cultured as described (Jiang et al., 2008).
Huh7.5 and MDBK cells stably expressing ISG20, the catalytically
inactive mutant ISG20, ISG20L1, or the control vector were estab-
lished by transducing cells with replication incompetent retroviruses
encoding WT (pCX4Bsr-ISG20-myc), D94G mutant ISG20 (pCX4Bsr-
ISG20m-myc), ISG20L1 (pCX4Bsr-ISG20L1), or the empty pCX4bsr
vector, respectively, followed by selection with 5 μg/ml of blasticidin
(Invivogen) for ~3 weeks, as described previously (Chen et al., 2007;
Wang et al., 2009). Replicon RNAs were transfected into Huh7.5
derived cells using DMRIE-C transfection reagent (Invitrogen) at a
ratio of 5 μg of lipid to 1 μg of RNA, as described (Lanford et al., 2003).
DNA transfection of Huh7.5 derived cells was conducted using
TransIT-LT1 (Mirus) per manufacturer's instructions. In some experi-
ments, replicon RNAs and plasmids were cotransfected into Huh7
cells using Lipofectamine 2000 as suggested by the manufacturer
(Invitrogen).
Viruses
Cell culture derived HCV (JFH1 virus) stocks were produced by
transfection of Huh7.5 cells with in vitro transcribed JFH1 RNA and
titrated by FFU assay following immunostaining of HCV core as
described (Wakita et al., 2005; Yi et al., 2006). The cytopathic NADL
strain of BVDVwas a gift from I. Frolov. BVDV stocks were prepared in
MDBK cells and titrated by TCID50 assay. The Urbani strain of SARS-
CoV was provided by L.M. Haynes and T. G. Ksiazek at the Centers for
Disease Control and Prevention, Atlanta, GA. SARS-CoV stocks were
grown and titrated in Vero E6 cells (Devaraj et al., 2007). Wild-type
YFV Asibi strain was provided by Dr. Robert Tesh (University of Texas
Medical Branch (UTMB), Galveston TX and World Reference Collec-
tion for Emerging Viruses and Arboviruses [WRCEVA]). The vaccine
strain, YFV 17-D-204, was derived from the 17-D infectious clone
(Rice et al., 1989) and was provided by Dr. Alan Barrett (UTMB). YFV
stocks were grown in VERO-E6 cells (ATCC) and harvested 4 days
post-infection or when cytopathic effects were ﬁrst visible. HM175/
18f is a rapidly replicating, cell culture-adapted variant of HAV
(Lemon et al., 1991). Working stocks were produced in Huh7 cells.
Experiments involving virulent YFV and SARS-CoV were conducted in
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(Cantell strain) were purchased from Charles River Laboratories.
Virus titration assays
Infectious progeny virus yields in cell-free culture supernatants of
HCV and YFV infected cultures were determined by focus forming assay
and viral titers were expressed as FFU/ml. Details for HCV FFU titration
assay has been presented elsewhere (Wakita et al., 2005; Yi et al., 2006).
For titration of YFV yields, Vero-E6 cells were infected with the serial
dilutions from time course supernatant samples for 1 h at 37 °C, 5% CO2
with occasional rocking followed by an overlay of 1% agarose/1X MEM
(Sigma) supplementedwith 2% bovine growth serum (Hyclone). Plates
were incubated for 4 days at 37 °C, 5% CO2 and then ﬁxed with 10%
buffered formalin (Sigma). Cells were permeabilized with 70% ethanol,
washed twice with PBS, and anti-YFVmouse hyperimmune ascitic ﬂuid
(kindly provided by Robert Tesh, WRCEVA) in PBS solution containing
5%milk and 1% Tween 20 (Sigma) were added and incubated overnight
with rocking. Cells were then washed twice with PBS and incubated
with goat anti-mouse IgG HRP-conjugated antibody (Dako) in solution
with PBS supplemented with 1% non-sterile bovine growth serum and
incubated for 5 h at room temperature. Cells were washed twice with
PBS followed by staining with AEC Substrate Chromagen (Dako) focus
forming unit visualization.
BVDV and SARS-CoV infectious progeny virus yields were deter-
mined by a standard TCID50 assay based on observation of cytopathic
effect on MDBK (for BVDV NADL) and Vero E6 (for SARS-CoV) cell
monolayers in96-well plateswith a series of 10-fold-diluted samples, as
described (Devaraj et al., 2007). The titer was expressed as TCID50/ml.
The titer of infectious HAVwas determined by an infra-red ﬂuorescence
focus assay as described (Jangra et al., 2010).
HCV RNA stability assay
Five millions of 7.5-Bsr, 7.5-ISG20 and 7.5-ISG20m cells were
electroporated with 5 μg of in vitro transcribed SGRmJFH1BlaRL/GND
or NmLuc/ΔGDD RNAs using a BioRad GenePulser XCell system. The
parameters used were 160 V, 500 μF, and maximum resistance. After
electroporation, cells were cultured in 12-well plates for the indicated
timeperiods prior to cell lysis (fromduplicatedwells) in 1X passive lysis
buffer (Promega) and measurement of Renilla (for SGRmJFH1BlaRL/
GND RNA transfected cells) or Fireﬂy (for NmLuc/ΔGDD RNA trans-
fected cells) luciferase activities in cell lysates. The luciferase activity at
3 hpost transfectionwas set as 100% for calculation of percent luciferase
activities at later time points, which were used to compare the rate of
HCV RNA degradation.
RT-PCR
Following the indicated treatments, total cellular RNA was
extracted from Huh7, 7.5-Bsr and 7.5-ISG20m cells using TRIzol
reagent (Invitrogen) and treated with DNase I to remove genomic
DNA contamination. The abundance of cellular mRNAs speciﬁc to
human ISG56 and MxA genes was determined by quantitative real-
time RT-PCR using commercially available primers and Taqman
probes (Applied Biosystems). ISG20 mRNA quantiﬁcation was con-
ducted by SYBR green-based quantitative real-time RT-PCR using
primers ISG20-409-F (5′-CTCCTGCACAAGAGCATCCA-3′) and ISG20-
474-R (5′-CGTTGCCCTCGCATCTTC-3′).
Immunoblot analysis
Cellular extracts were prepared and subjected to immunoblot
analysis asdescribed (Li et al., 2005a,b). The followingmAbsorpolyclonal
(pAb) antibodieswere used: anti-FLAGM2and anti-actinmAbs (Sigma);
anti-myc tagmAb9B11(Cell Signaling Tech.); anti-ISG20mAb(Abnova);rabbit anti-YFV NS3 pAb (from Charles Rice); rabbit anti-core pAb (from
John McLauchlan); K24F2 anti-HAV mAb (Commonwealth Serum
Institute), rabbit anti-ISG56 pAb (Wang et al., 2009); anti-Sendai virus
pAb (from Ilkka Julkunen); rabbit anti-SARS-CoV N pAb (Imgenex);
peroxidase-conjugated secondary goat anti-rabbit, and goat anti-mouse
pAbs (Southern Biotech). Protein bands were visualized using enhanced
chemiluminescence (Millipore), followed by exposure to X-ray ﬁlms.
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